Sort   by:  
 Page size 
GenomicsExpression analysis after co-treatment of GSK126 and pomalidomide
Expression analysis after co-treatment of GSK126 and pomalidomide
PRJNA613728 | ENA
GenomicsPomalidomide inhibits PD-L1 induction to promote anti-tumor immunity
Pomalidomide inhibits PD-L1 induction to promote anti-tumor immunity
PRJNA494725 | ENA
GenomicsPomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)
Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)
PRJNA1231602 | ENA
GenomicsPomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)
Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)
PRJNA1231600 | ENA
GenomicsPomalidomide as an immune-enhancing agent in samples from people living with HIV
Pomalidomide as an immune-enhancing agent in samples from people living with HIV
PRJNA1021527 | ENA
TranscriptomicsExpression analysis after co-treatment of GSK126 and pomalidomide
To determine combination effect of GSK126 and pomalidomide at the RNA levels in EZH2 Y641 mutant DLBCL, We performed gene expression profiling in WSU-DLCL2 cell line after co-treatment of GSK126 and pomalidomide
ORGANISM(S): Homo sapiens 
2020-09-23 | GSE147320 | GEO
UnknownPopulation pharmacokinetics of pomalidomide.
Not available
S-EPMC4418344 | biostudies-literature
TranscriptomicsCereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide
This SuperSeries is composed of the following subset Series: GSE31421: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [expression profiling] GSE31451: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [aCGH]...
ORGANISM(S): Homo sapiens 
2011-09-30 | E-GEOD-31452 | biostudies-arrayexpress
TranscriptomicsPomalidomide as an immune-enhancing agent in samples from people living with HIV
Persisting immune dysfunction in people living with HIV (PLHIV) on suppressive antiretroviral therapy (ART) is a key challenge to finding a cure for HIV. We investigated pomalidomide, a well-tolerated immunomodulatory drug, as an agent to enhance HIV-directed immune responses. We collected periphera...
ORGANISM(S): Homo sapiens 
2025-12-09 | GSE244148 | GEO
TranscriptomicsPomalidomide inhibits PD-L1 induction to promote anti-tumor immunity
We examined genome-wide how pomalidomide affects IFN-gamma-induced PD-L1 expression in human melanoma cell line.
ORGANISM(S): Homo sapiens 
2018-10-08 | GSE120844 | GEO
Sort   by:  
 Page size